Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors and Incidence of Adverse Events in Patients with Type 2 Diabetes

제2형 당뇨병 환자에서 Dapagliflozin이 혈당과 심혈관계질환 위험인자에 미치는 영향 및 안전성

  • Lee, Hye Jin (Department of Pharmacy, Yonsei University Health System) ;
  • Geum, Min Jung (Department of Pharmacy, Yonsei University Health System) ;
  • Kim, Jae Song (Department of Pharmacy, Yonsei University Health System) ;
  • Kim, Soo Hyun (Department of Pharmacy, Yonsei University Health System) ;
  • Son, Eun Sun (Department of Pharmacy, Yonsei University Health System)
  • 이혜진 (연세대학교 세브란스병원 약무국) ;
  • 금민정 (연세대학교 세브란스병원 약무국) ;
  • 김재송 (연세대학교 세브란스병원 약무국) ;
  • 김수현 (연세대학교 세브란스병원 약무국) ;
  • 손은선 (연세대학교 세브란스병원 약무국)
  • Received : 2017.10.02
  • Accepted : 2017.12.17
  • Published : 2017.12.29
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Dapagliflozin is an oral selective inhibitor of sodium-glucose cotransporter 2(SGLT2), the kidney transporter chiefly responsible for glucose reabsorption from the glomerular filtrate. Because this mechanism does not require the action of insulin, dapagliflozin rarely causes hypoglycemia. Dapagliflozin may affect blood glucose control as well as blood pressure and the body weight which are one of the cardiovascular disease risk factors. However, dehydration and ketoacidosis are reported as the side effects of the dapagliflozin treatment and the safety issues have been occurred. The aim of this study is to analyze the effectiveness and adverse events of dapagliflozin in Korean patients. Methods: From December 2014 to August 2015, we retrospectively reviewed the electronic medical records of type 2 diabetes patients who were prescribed dapagliflozin at Severance Hospital. Results: A total of 202 Korean patients were enrolled in this study. The effectiveness in the reduction of blood glucose was statistically significant(p<0.001). Dapagliflozin decreased 0.74% of HbA1c after 24 weeks. Significantly more participants achieved the target HbA1c level(HbA1c<7%) after 24 weeks(n=42, 35.3%) than before taking dapagliflozin(n=21, 17.6%). Blood pressure decreased 5.7 mmHg systolic blood pressure(SBP), 1.9 mmHg diastolic blood pressure(DBP) after 24 weeks. More than one quarter of participants(n=35, 29.4%) experienced weight loss. Most common adverse event was genitourinary symptoms. Conclusion: In this study, the effectiveness of dapagliflozin in improving glycemic control, blood pressure control, and weight loss was statistically significant. However, elderly and female patients, who have higher incidence of adverse events, should use dapagliflozin cautiously.

Keywords

References

  1. Park Y, et al. Prevalence of diabetes and IGT in Yonchon County, South Korea. Diabetes Care 1995;18: 545-8. https://doi.org/10.2337/diacare.18.4.545
  2. Korean Diabetes Association. Diabetes fact sheet in Korea. 2016;8-28.
  3. Plosker GL. Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes. Drugs 2014;74: 2191-09. https://doi.org/10.1007/s40265-014-0324-3
  4. Scheen AJ. Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 2015;75:33-59. https://doi.org/10.1007/s40265-014-0337-y
  5. Ptaszynska A, et el. Effects of Dapagliflozin on Cardiovascular Risk Factors. Postgraduate Medicine 2013;3:125.
  6. Kosuke Tauchi. 10 deaths reported following use of newly marketed diabetes drugs. The Asahi Shimbun, 2015, Jan.
  7. Korean Food and Drug Administration. Pharmaceuticals and Medical Devices Agency(PMDA) "SGLT2 inhibitors" permitted articles. 2015, Jan.
  8. Korean Food and Drug Administration. Forxiga permitted articles Available from http://ezdrug.mfds.go.kr/kfda2. Accessed April 24, 2017
  9. YANG W et al. Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis. J Diabetes 2017;9(8):787-9. https://doi.org/10.1111/1753-0407.12484
  10. World Heart Federation. Cardiovascular Risk Factors. http://www.world-heart-federation.org/press/fact-sheets/cardiovascular-diseaserisk-factors. Accessed April 24, 2017
  11. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatments or prevention of diabetes mellitus. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed Feburary 24, 2016.
  12. Bailey CJ. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33. https://doi.org/10.1016/S0140-6736(10)60407-2
  13. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6. https://doi.org/10.7326/0003-4819-122-7-199504010-00001
  14. Korean Diabetes Association. 2015 Treatment guideline for diabetes (5th edition). Avaible form http://www.diabetes.or.kr/func/download.php? Accessed April 24, 2017.
  15. Silvio E, Inzucchi, et al. Management of Hyperglycemia in Type 2 Diabetes 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38(1):140-9. https://doi.org/10.2337/dc14-2441
  16. Bakris GL, Gaxiola E, Messerli FH, et al. INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004;44:637-42. https://doi.org/10.1161/01.HYP.0000143851.23721.26
  17. ACCORD Study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 29;362(17):1575-85.
  18. Hamren B, Bjork E, Sunzel M, et al. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 2018;84:228-35.